|
1
|
Panciera T, Azzolin L, Fujimura A, Di
Biagio D, Frasson C, Bresolin S, Soligo S, Basso G, Bicciato S,
Rosato A, et al: Induction of expandable tissue-specific
stem/progenitor cells through transient expression of YAP/TAZ. Cell
Stem Cell. 19:725–737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mauviel A, Nallet-Staub F and Varelas X:
Integrating developmental signals: A Hippo in the (path)way.
Oncogene. 31:1743–1756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nishioka N, Inoue K, Adachi K, Kiyonari H,
Ota M, Ralston A, Yabuta N, Hirahara S, Stephenson RO, Ogonuki N,
et al: The Hippo signaling pathway components Lats and Yap Pattern
TEAD4 activity to distinguish mouse trophectoderm from inner cell
mass. Dev Cell. 16:398–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xin M, Kim Y, Sutherland LB, Murakami M,
Qi X, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, et
al: Hippo pathway effector Yap promotes cardiac regeneration. Proc
Natl Acad Sci USA. 110:13839–13844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stampouloglou E and Varelas X:
Phosphatidic acid signals via the Hippo pathway. Mol Cell.
72:205–206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heallen T, Zhang M, Wang J,
Bonilla-Claudio M, Klysik E, Johnson RL and Martin JF: Hippo
pathway inhibits Wnt signaling to restrain cardiomyocyte
proliferation and heart size. Science. 332:458–461. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Varelas X, Miller BW, Sopko R, Song S,
Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill
H, et al: The Hippo pathway regulates Wnt/β-catenin signaling. Dev
Cell. 18:579–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhuang J, Lin S, Dong L, Cheng K and Weng
W: Magnetically actuated mechanical stimuli on
Fe3O4/mineralized collagen coatings to
enhance osteogenic differentiation of the MC3T3-E1 cells. Acta
Biomater. 71:49–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhuang J, Lin S, Dong L, Cheng K and Weng
W: Magnetically assisted electrodeposition of aligned collagen
coatings. ACS Biomater Sci Eng. 4:52018.
|
|
11
|
Regimbald-Dumas Y and He X: Wnt
signalling: What the X@# is WTX? EMBO J. 30:1415–1417. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
MacDonald BT, Tamai K and He X:
Wnt/β-Catenin signaling: Components, mechanisms, and diseases. Dev
Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sebastian R, Michael SK, Katerina G,
Sanjay K and David VS: Dynamics of mechanosensitive neural stem
cell differentiation. Stem Cells. 35:497–506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang
H, Guan KL and Xu Y: Structural insights into the YAP and TEAD
complex. Genes Dev. 24:235–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Imajo M, Miyatake K, Iimura A, Miyamoto A
and Nishida E: A molecular mechanism that links Hippo signalling to
the inhibition of Wnt/β-catenin signalling. EMBO J. 31:1109–1122.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Azzolin L, Panciera T, Soligo S, Enzo E,
Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V,
et al: YAP/TAZ incorporation in the β-catenin destruction complex
orchestrates the Wnt response. Cell. 158:157–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J and Martin JF: Hippo pathway: An
emerging regulator of craniofacial and dental development. J Dent
Res. 96:1229–1237. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng F, Peng L, Li Z, Tan G, Liang E, Chen
S, Zhao X and Zhi F: YAP triggers the Wnt/β-catenin signalling
pathway and promotes enterocyte self-renewal, regeneration and
tumorigenesis after DSS-induced injury. Cell Death Dis. 9:1532018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sansom OJ, Griffiths DF, Reed KR, Winton
DJ and Clarke AR: Apc deficiency predisposes to renal carcinoma in
the mouse. Oncogene. 24:8205–8210. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saadi-Kheddouci S, Berrebi D, Romagnolo B,
Cluzeaud F, Peuchmaur M, Kahn A, Vandewalle A and Perret C: Early
development of polycystic kidney disease in transgenic mice
expressing an activated mutant of the beta-catenin gene. Oncogene.
20:5972–5981. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dupont S, Morsut L, Aragona M, Enzo E,
Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M,
Bicciato S, et al: Role of YAP/TAZ in mechanotransduction. Nature.
474:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuroda M, Wada H, Kimura Y, Ueda K and
Kioka N: Vinculin promotes nuclear localization of TAZ to inhibit
ECM stiffness-dependent differentiation into adipocytes. J Cell
Science. 130:989–1002. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Papaspyropoulos A, Bradley L, Thapa A,
Leung CY, Toskas K, Koennig D, Pefani DE, Raso C, Grou C, Hamilton
G, et al: RASSF1A uncouples Wnt from Hippo signalling and promotes
YAP mediated differentiation via p73. Nat Commun. 9:4242018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park HW, Kim YC, Yu B, Moroishi T, Mo JS,
Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM, et al: Alternative
Wnt signaling activates YAP/TAZ. Cell. 162:780–794. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Du S, Lei T, Wang H, He X, Tong R
and Wang Y: Multifaceted regulation and functions of YAP/TAZ in
tumors (Review). Oncol Rep. 40:16–28. 2018.PubMed/NCBI
|
|
26
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsutsumi R, Masoudi M, Takahashi A, Fujii
Y, Hayashi T, Kikuchi I, Satou Y, Taira M and Hatakeyama M: YAP and
TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2
function. Dev Cell. 26:658–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takahashi A, Tsutsumi R, Kikuchi I, Obuse
C, Saito Y, Seidi A, Karisch R, Fernandez M, Cho T, Ohnishi N, et
al: SHP2 tyrosine phosphatase converts parafibromin/cdc73 from a
tumor suppressor to an oncogenic driver. Mol Cell. 43:45–56. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan J, Xiong L, Zhao K, Zeng P, Wang B,
Tang FL, Sun D, Guo HH, Yang X, Cui S, et al: YAP promotes
osteogenesis and suppresses adipogenic differentiation by
regulating β-catenin signaling. Bone Res. 6:182018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang B, Sun H, Song F, Yu M, Wu Y and Wang
J: YAP1 negatively regulates chondrocyte differentiation partly by
activating the β-catenin signaling pathway. Cell. 87:104–113.
2017.
|
|
31
|
Zhao K, Shen C, Lu Y, Huang Z, Li L, Rand
CD, Pan J, Sun XD, Tan Z, Wang H, et al: Muscle Yap is a regulator
of neuromuscular junction formation and regeneration. J Neurosci.
37:3465–3477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Urban ML, Manenti L and Vaglio A:
Fibrosis-a common pathway to organ injury and failure. N Engl J
Med. 373:95–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Henderson WR Jr, Chi EY, Ye X, Nguyen C,
Tien YT, Zhou B, Borok Z, Knight DA and Kahn M: Inhibition of
Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses
pulmonary fibrosis. Proc Natl Acad Sci USA. 107:14309–14314. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Satoh M, Nagasu H, Morita Y, Yamaguchi TP,
Kanwar YS and Kashihara N: Klotho protects against mouse renal
fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol.
303:F1641–F1651. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang M, Chen DQ, Chen L, Liu D, Zhao H,
Zhang ZH, Vaziri ND, Guo Y, Zhao YY and Cao G: Novel RAS inhibitors
poricoic acid ZG and poricoic acid ZH attenuate renal fibrosis via
a Wnt/β-catenin pathway and targeted phosphorylation of smad3
signaling. J Agric Food Chem. 66:1828–1842. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Noguchi S, Saito A and Nagase T: YAP/TAZ
signaling as a molecular link between fibrosis and cancer. Int J
Mol Sci. 19:36742018. View Article : Google Scholar
|
|
37
|
Haak AJ, Kostallari E, Sicard D, Ligresti
G, Choi KM, Caporarello N, Jones DL, Tan Q, Meridew J, Diaz
Espinosa AM, et al: Selective YAP/TAZ inhibition in fibroblasts via
dopamine receptor D1 agonism reverses fibrosis. Sci Transl Med.
11:eaau62962019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Toyama T, Looney AP, Baker BM, Stawski L,
Haines P, Simms R, Szymaniak AD, Varelas X and Trojanowska M:
Therapeutic targeting of TAZ and YAP by dimethyl fumarate in
systemic sclerosis fibrosis. J Invest Dermatol. 138:78–88. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu H, Ge T, Pan Y and Zhang S: Advanced
role of Hippo signaling in endometrial fibrosis: Implications for
intrauterine adhesion. Chin Med J (Engl). 130:2732–2737. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Verma S, Yeddula N, Soda Y, Zhu Q, Pao G,
Moresco J, Diedrich JK, Hong A, Plouffe S, Moroishi T, et al:
BRCA1/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1
signaling. Proc Natl Acad Sci USA. 116:7363–7370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zanconato F, Forcato M, Battilana G,
Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M
and Piccolo S: Genome-wide association between YAP/TAZ/TEAD and
AP-1 at enhancers drives oncogenic growth. Nat Cell Biol.
17:1218–1227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moya IM and Halder G: Hippo-YAP/TAZ
signalling in organ regeneration and regenerative medicine. Nat Rev
Molr Cell Biol. 20:211–226. 2019. View Article : Google Scholar
|
|
43
|
Sulaiman A, McGarry S, Li L, Jia D, Ooi S,
Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, et al: Dual
inhibition of Wnt and Yes-associated protein signaling retards the
growth of triple negative breast cancer in both mesenchymal and
epithelial states. Mol Oncol. 12:423–440. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hu J, Gao C, Chen G and Gao X: Abstract
LB-310: PYK2 as a therapeutic target for pancreatic cancer. Cancer
Res. 77:3102017.
|
|
45
|
Szalmás A, Tomaić V, Basukala O, Massimi
P, Mittal S, Kónya J and Banks L: The PTPN14 tumor suppressor is a
degradation target of human papillomavirus E7. J Virol.
91:e00057–00017. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tao J, Calvisi DF, Ranganathan S, Cigliano
A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger
S, et al: Activation of β-Catenin and Yap1 in human hepatoblastoma
and induction of hepatocarcinogenesis in mice. Gastroenterology.
147:690–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rosenbluh J, Nijhawan D, Cox AG, Li X,
Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et
al: β-catenin-driven cancers require a YAP1 transcriptional complex
for survival and tumorigenesis. Cell. 151:1457–1473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kartha VK, Alamoud KA, Sadykov K, Nguyen
BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, et al:
Functional and genomic analyses reveal therapeutic potential of
targeting β-catenin/CBP activity in head and neck cancer. Genome
Med. 10:542018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Santucci M, Vignudelli T, Ferrari S, Mor
M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The Hippo
pathway and YAP/TAZ-TEAD protein-protein interaction as targets for
regenerative medicine and cancer treatment. J Med Chem.
58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu-Chittenden Y, Huang B, Shim JS, Chen
Q, Lee SJ, Anders RA, Liu JO and Pan D: Genetic and pharmacological
disruption of the TEAD-YAP complex suppresses the oncogenic
activity of YAP. Genes Dev. 26:1300–1305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rozengurt E, Sinnett-Smith J and Eibl G:
Yes-associated protein (YAP) in pancreatic cancer: At the epicenter
of a targetable signaling network associated with patient survival.
Signal Transduct Target Ther. 3:112018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Stampouloglou E, Cheng N, Federico A,
Slaby E, Monti S, Szeto GL and Varelas X: Yap suppresses T-cell
function and infiltration in the tumor microenvironment. PLoS Biol.
18:e30005912020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Crawford JJ, Bronner SM and Zbieg JR:
Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: A
patent review. Expert Opin Ther Pat. 28:867–873. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hsu PC, Jablons DM, Yang CT and You L:
Epidermal growth factor receptor (EGFR) pathway, Yes-associated
protein (YAP) and the regulation of programmed death-ligand 1
(PD-L1) in non-small cell lung cancer (NSCLC). Int J Mol Sci.
20:38212019. View Article : Google Scholar
|
|
55
|
Hsu PC, Yang CT, Jablons DM and You L: The
role of Yes-associated protein (YAP) in regulating programmed
death-ligand 1 (PD-L1) in thoracic cancer. Biomedicines. 6:1142018.
View Article : Google Scholar
|
|
56
|
Alam M, Bouillez A, Tagde A, Ahmad R,
Rajabi H, Maeda T, Hiraki M, Suzuki Y and Kufe D: MUC1-C represses
the crumbs complex polarity factor CRB3 and downregulates the Hippo
pathway. Mol Cancer Res. 14:1266–1276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
